COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) introduced as we speak that the Firm was not too long ago engaged by Public Well being England (PHE) and the Medicines and Well being Merchandise Regulatory Company (MHRA) to produce its IMVANEX® smallpox vaccine in response to new circumstances of monkeypox within the UK. Two associated circumstances had been confirmed and admitted to a hospital in Liverpool. One was most certainly contaminated in Africa, the place the household arrived from a couple of days earlier than onset of illness, and a sibling case most certainly contaminated on UK soil by the primary case.
Monkeypox is a uncommon, however severe illness, which is endemic in Central and West Africa. The illness is sort of just like human smallpox, though it’s much less extreme with an estimated fatality price of 1-10%.
IMVANEX (MVA-BN) is permitted by the European Fee for lively immunization in opposition to smallpox however has additionally acquired approval for monkeypox by the U.S. Meals and Drug Administration (FDA) and Well being Canada, as the one vaccine permitted for this indication in these territories. Bavarian Nordic beforehand delivered IMVANEX to PHE in reference to the primary human circumstances of monkeypox within the UK in 2018 and later in 2019, when a number of unrelated human circumstances had been imported from Nigeria with a subsequent an infection of a healthcare employee within the UK.
Paul Chaplin, President and CEO of Bavarian Nordic stated: “We’re happy to help Public Well being England quickly in such an emergency scenario. Vaccination is a crucial measure to forestall and management the unfold of ailments globally. Governments have a necessary function in getting ready for outbreaks by stockpiling vaccines and coverings in order that they’re available in occasions like this. Now we have an extended historical past of working with different governments on strengthening their nationwide preparedness in outbreak conditions, and we urge extra nations to actively think about and mitigate the dangers of ailments like monkeypox, which sadly is on the rise in Africa and has in recent times proven to cross borders a number of occasions.”
About Bavarian Nordic
Bavarian Nordic is a totally built-in vaccines firm centered on the event, manufacture and commercialization of life-saving vaccines. We’re a world chief in smallpox vaccines and have been a long-term provider to the U.S. Authorities of a non-replicating smallpox vaccine, which has been permitted by the FDA underneath the commerce identify JYNNEOS®, additionally for the safety in opposition to monkeypox. The vaccine is permitted as a smallpox vaccine in Europe underneath the commerce identify IMVANEX® and in Canada underneath the commerce identify IMVAMUNE®. Our industrial product portfolio moreover incorporates the market-leading vaccine Rabipur®/RabAvert® in opposition to rabies and Encepur® in opposition to tick-borne encephalitis. Utilizing our stay virus vaccine platform know-how, MVA-BN®, we’ve created a various portfolio of proprietary and partnered product candidates designed to save lots of and enhance lives by unlocking the facility of the immune system, together with an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Firms of Johnson & Johnson. We’re additionally dedicated to the event of a subsequent technology COVID-19 vaccine based mostly on an in-licensed capsid virus-like particle know-how. The vaccine candidate, ABNCoV2, is at present being investigated in medical trials. For extra info go to www.bavarian-nordic.com.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, firstname.lastname@example.org, Tel: +1 781 686 9600